PTEN/AKT upregulation of TMSB10 contributes to lung cancer cell growth and predicts poor survival of the patients. Issue 4 (29th December 2020)

• Record Type: Journal Article
• Authors: Li, Jie; Zhou, Shaohui; Li, Hongchen; Xu, Yanzhao; Zhou, Ning; Liu, Rongfeng
• Is Part Of: Bioscience, biotechnology, and biochemistry. Volume 85:Issue 4(2021)
• Page Start: 805
• Page End: 813
• Publication Date: 2020-12-29
• Subjects: lung cancer -- PTEN/AKT -- TMSB10 -- proliferation -- migration; Biotechnology -- Periodicals; Biochemistry -- Periodicals; 660.6
• DOI: 10.1093/bbb/zbaa113
• Languages: English
• ISSNs: 0916-8451

Abstract

ABSTRACT: PTEN/AKT signaling cascade is frequently activated in various cancers, including lung cancer. The downstream effector of this signaling cascade is poorly understood. β-Thymosin 10 (TMSB10) functions as an oncogene or tumor suppressors in cancers, whereas its significance in lung cancer remains unknown. In this study, we showed that the activation of PTEN/AKT signaling promoted the expression of TMSB10. Based on the TCGA database, TMSB10 was upregulated in lung cancer tissues and its overexpression was correlated with poor prognosis of lung cancer patients. Functional experiments demonstrated that TMSB10 knockdown suppressed, while its overexpression promoted the proliferation, growth, and migration of lung cancer cells. Apoptosis and epithelial-mesenchymal transition were also regulated by TMSB10. We therefore suggest that TMSB10 is a novel oncogene for lung cancer. Targeting TMSB10 may benefit lung cancer patients with activated PTEN/AKT signaling. Graphical Abstract: